PRESS RELEASE
16 October 2025

Charles Boulakia On Building Connections At The AIPPI World Congress 2025

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
Principal Charles Boulakia joined the Canadian delegation at the AIPPI conference in Yokohama, Japan, from September 13-16. Below Charles provides some insights and highlights from the conference.
Canada

Principal Charles Boulakia joined the Canadian delegation at the AIPPI conference in Yokohama, Japan, from September 13-16. Below Charles provides some insights and highlights from the conference.

"Japan was an incredible host this year, pulling out all the stops. But the best part of the conference was catching up with old friends and making new ones."

Landmark patent resolution

Alongside esteemed colleagues Anita Nador, Santosh Chari and Fraser Rowand, the delegation successfully advanced Patent Resolution Q293, proposing a harmonized framework for compulsory licensing of patents in cases of overriding public interest, a significant step forward in global patent law.

178082a.jpg

Left to right: Fraser Rowand, Santosh Chari, Charles Boulakia, Anita Nador.

Chair of the Standing Committee on Pharma

Charles was honoured to be appointed Chair of the Standing Committee on Pharma, in a bittersweet announcement that marked the retirement of John Todaro, who has led the group for more than a decade. This committee of over 50 members from dozens of countries is one of the most active at AIPPI.

Publication of Volume 11 of the AIPPI Law Series

The event also marked the finalization of Volume 11 of the AIPPI Law Series, a monumental 473-page publication titled Experimental Use and Bolar Exemptions. Charles, alongside co-editors David Gilat and Daphné Derouane, celebrated this achievement with over 80 contributing authors — a true testament to collaborative scholarship in IP law.

178082b.jpg

Left to right: David Gilat, Daphné Derouane, Charles Boulakia.

Pharma Day highlights

"Pharma Day" featured four dynamic panel discussions addressing critical IP challenges in the pharmaceutical industry, many of which were organized and led by the Standing Committee on Pharma members, including Charles.

178082c.jpg

Leadership of the Pharma and Biotech committees, top to bottom: Daphné Derouane, Graeme Boocock, Daniel Lim, Juergen Meier, Charles Boulakia, and Martin Klok.

178082d.jpg

Left to right: John Todaro (standing), Martin Klok, Charles Boulakia, Juergen Meier, Daniel Lim, Graeme Boocock, and Daphné Derouane.

Cultural highlights from Japan

Beyond the conference, Charles and colleagues embraced the unique cultural experiences Japan had to offer — from sushi on conveyor belts and visits to the Seiko and Cupnoodles museums, to memorable evenings of karaoke and a captivating Kabuki theatre performance.

Charles Boulakia's participation in AIPPI 2025 reflects Smart & Biggar's ongoing leadership in international intellectual property law and its commitment to shaping the future of innovation worldwide.

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More